Stock NYMXF NYMOX PHARMACEUTICAL CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up

Financials Nymox Pharmaceutical Corporation

Equities

NYMXF

BSP733981026

Biotechnology & Medical Research

Market Closed - OTC Markets
Other stock markets
 03:33:57 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.3 USD 0.00% Intraday chart for Nymox Pharmaceutical Corporation +3.38% -49.15%
2023 Nymox Pharmaceutical Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Nymox Pharmaceutical Corporation Announces Submission of New Marketing Authorization Application Submission for NYMOZARFEX (TM) for BPH CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 180.9 83.47 153.9 191.8 110.2 29.51
Enterprise Value (EV) 1 180.1 75.53 148.8 188.7 109.8 28.28
P/E ratio -12.9 x -7.48 x -11.5 x -15.6 x -8.5 x -4.39 x
Yield - - - - - -
Capitalization / Revenue 808 x 279 x 1,327 x 38,368 x - -
EV / Revenue 804 x 253 x 1,283 x 37,731 x - -
EV / EBITDA -13.6 x -7.1 x -11.2 x -16.1 x -8.79 x -4.26 x
EV / FCF -146 x -19.3 x -50.7 x -33.2 x -21.3 x -10 x
FCF Yield -0.69% -5.17% -1.97% -3.01% -4.69% -10%
Price to Book -149 x 12.1 x 45.4 x 90.1 x -220 x -60.7 x
Nbr of stocks (in thousands) 54,832 63,719 69,969 77,354 84,796 91,265
Reference price 2 3.300 1.310 2.200 2.480 1.300 0.3233
Announcement Date 3/29/18 3/29/19 3/30/20 3/29/21 3/30/22 5/2/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.224 0.299 0.116 0.005 - -
EBITDA 1 -13.23 -10.64 -13.32 -11.71 -12.49 -6.64
EBIT 1 -13.24 -10.64 -13.32 -11.72 -12.5 -6.652
Operating Margin -5,908.48% -3,558.86% -11,487.07% -234,400% - -
Earnings before Tax (EBT) 1 -13.43 -10.59 -13.16 -11.74 -12.54 -6.576
Net income 1 -13.43 -10.59 -13.16 -11.74 -12.54 -6.576
Net margin -5,995.09% -3,543.14% -11,346.55% -234,760% - -
EPS 2 -0.2551 -0.1752 -0.1912 -0.1590 -0.1529 -0.0736
Free Cash Flow 1 -1.234 -3.906 -2.938 -5.675 -5.147 -2.828
FCF margin -550.98% -1,306.31% -2,532.65% -113,505% - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/29/18 3/29/19 3/30/20 3/29/21 3/30/22 5/2/23
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 0.85 7.95 5.09 3.19 0.44 1.23
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.23 -3.91 -2.94 -5.68 -5.15 -2.83
ROE (net income / shareholders' equity) 1,800% -368% -252% -420% -1,530% 1,331%
ROA (Net income/ Total Assets) -545% -147% -123% -149% -270% -271%
Assets 1 2.464 7.212 10.72 7.878 4.641 2.426
Book Value Per Share 2 -0.0200 0.1100 0.0500 0.0300 -0.0100 -0.0100
Cash Flow per Share 2 0.0200 0.1200 0.0700 0.0500 0.0100 0.0200
Capex - 0.04 - 0.01 0.01 -
Capex / Sales - 12.04% - 260% - -
Announcement Date 3/29/18 3/29/19 3/30/20 3/29/21 3/30/22 5/2/23
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
NYMOX PHARMACEUTICAL CORPORATION Stock Nymox Pharmaceutical Corporation
-49.15% 28.01M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+49.22% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NYMXF Stock
  4. Financials Nymox Pharmaceutical Corporation